John Butler, President of Personalized Genetic Health at Genzyme, presented at last year's World Orphan Drug Congress USA on the topic â€˜Genzyme's patient-focused approach in the rare disease sector.'
Do you want to learn more about:
- Patient-centered drug development – the key to orphan drug success
- Successful development through collaboration
- Building sustainable healthcare systems
- Win-win-win solutions: for whom and how?
If so, you need to check out the video below: